Gilead Sciences, Inc. (GILD) Holdings Lifted by Parkwood LLC

Parkwood LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 116.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,469 shares of the biopharmaceutical company’s stock after purchasing an additional 8,869 shares during the quarter. Parkwood LLC’s holdings in Gilead Sciences were worth $1,334,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the business. FMR LLC increased its stake in shares of Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after acquiring an additional 258,005 shares during the period. Investment Centers of America Inc. increased its stake in shares of Gilead Sciences by 7.2% in the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after acquiring an additional 1,958 shares during the period. Vanguard Group Inc. increased its stake in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after acquiring an additional 2,148,697 shares during the period. Northern Trust Corp increased its stake in shares of Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after acquiring an additional 116,780 shares during the period. Finally, Fagan Associates Inc. increased its stake in shares of Gilead Sciences by 2.6% in the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock worth $2,341,000 after acquiring an additional 845 shares during the period. Institutional investors and hedge funds own 75.94% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $74.52 on Friday. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The stock has a market cap of $98,130.00, a price-to-earnings ratio of 8.48, a price-to-earnings-growth ratio of -1.59 and a beta of 1.13. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s revenue was down 13.2% compared to the same quarter last year. During the same period last year, the firm posted $2.75 earnings per share. equities research analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.79%. The ex-dividend date was Thursday, December 14th. Gilead Sciences’s payout ratio is 23.66%.

Several analysts recently commented on GILD shares. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, October 19th. Royal Bank of Canada started coverage on shares of Gilead Sciences in a research report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price target on the stock. JPMorgan Chase & Co. set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Credit Suisse Group restated a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, December 7th. Finally, Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $85.03.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the transaction, the insider now directly owns 3,070,099 shares of the company’s stock, valued at $230,656,537.87. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the transaction, the executive vice president now directly owns 77,363 shares in the company, valued at $5,788,299.66. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 461,666 shares of company stock worth $34,072,567. Insiders own 1.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2018/01/06/gilead-sciences-inc-gild-holdings-lifted-by-parkwood-llc.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply